Merck profit beats estimates as Keytruda sales surge

Merck & Co Inc reported a better-than-expected quarterly profit on Tuesday and raised its full-year earnings forecast as sales of its blockbuster immunotherapy, Keytruda, crossed the $3 billion mark for the first time in a single quarter.